Combinational Therapy of Acute Lymphoblastic Leukemia with Cyclophosphamide and BV6 Synergistically Induces Apoptosis in Leukemic Cells

Background: Acute lymphoblastic leukemia (ALL), a hematological malignancy, is associated with the accumulation of lymphoblasts in hematopoietic tissues and peripheral blood (PB). A major obstacle ALL treatment failure to undergo apoptosis, thus resulting relapses. Cyclophosphamide an alkylating agent widely used treat various cancers. BV6 another agent, under preclinical clinical trials, which inhibits function inhibitors apoptosis proteins (IAPs) cells. According previous studies, IAPs are highly overexpressed Also, intrinsic pathway reported be dysfunctional cells, making new promising option due its potential induce extrinsic cell death as well. Methods: In current study, inhibitory effect combinational cyclophosphamide was studied on growth eleven patients using MTT test. Subsequently, TNF-α secretion Finally, we measured DNA fragmentation rates treated cells Results: The results indicated synergistic between drugs viability impact cotreatment increased time-dependent manner. We also found that BV6, but not cyclophosphamide, induces secretion, activating Conclusion: by inducing pathways, overcomes resistance. These suggest use for patients. Inhibition helps overcome can improve prognosis